Video

Dr. Balar on Rationale for KEYNOTE-057 in NMIBC

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the rationale for the KEYNOTE-057 study in patients with non–muscle invasive bladder cancer.

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the rationale for the KEYNOTE-057 study in patients with non—muscle invasive bladder cancer (NMIBC).

The study, which was presented by Balar at the 2019 Genitourinary Cancers Symposium, aimed to test the efficacy of pembrolizumab (Keytruda) in a specific subset of patients with NMIBC. These were patients with high-risk disease who previously received Bacillus Calmette-Guérin (BCG), an intravesical immunotherapy, and became unresponsive to the treatment.

Historically, these patients would be treated with radical cystectomy—complete surgical removal of the bladder. This was done because with BCG unresponsive disease, the natural history of the disease is to progress toward muscle invasive and, eventually, metastatic disease. Radical cystectomy was felt to be the only curative strategy for these patients. In this setting is where the PD-1 inhibitor pembrolizumab was tested, with the hope that these patients can ultimately preserve their bladders.

<<< 2019 Genitourinary Cancers Symposium

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity